- Published on Jul 28, 2008
The study consisted of older Mexican-Americans in Sacramento, Calif., who suffered from metabolic conditions that put them at risk for developing dementia, Alzheimer's or cognitive impairment without dementia, said Mary Haan, epidemiology professor at the University of Michigan School of Public Health and lead author of the study. Some of the risk factors for dementia include high cholesterol, Type 2 diabetes, obesity and hypertension.
"The bottom line is that if a person takes statins over a course of about 5-7 years, it reduces the risk of dementia by half, and that's a really big change," said Haan, who notes that the study did not look at statins as a treatment for existing dementia, only as a preventative. Statins are drugs that specifically lower LDL or bad cholesterol.
The longitudinal study was originally funded in 1997 to look at metabolic and vascular conditions like hypertension and diabetes and their effect on the risk of dementia and Alzheimer's disease. Earlier landmark findings by Haan's group of the same study cohort established that certain metabolic and vascular disorders predicted Alzheimer's and dementia. For instance, people with Type 2 diabetes are up to three times more likely to develop Alzheimer's disease, they found.
In this current study, Haan's group set out to measure whether taking statins over time lowered the development of dementia in that same high-risk population. The resulting paper, "Use of Statins and Incidence of Cognitively Impaired Not Demented and Dementia in a Cohort Study," will appear in the July 29 issue of Neurology.
"In older people you have so many different chronic conditions, especially in this group, that the chance of any intervention having an effect is fairly limited," Haan said. "Say you're 75 or 80 and you've got six diseases. How much is a treatment really going to help? This showed if you started using statins before the dementia developed you could prevent it in about half of the cases."
It's likely that many people taking statins have already benefited unknowingly from the dementia fighting properties, she said. Haan hopes the study will help fuel randomized trials to test statins and their ability to prevent dementia.
Of 1,674 participants who were free of dementia at the start of the study, 27 percent, or 452 people, took statins at some point in the study. Over the five-year follow up period, 130 participants developed dementia or cognitive impairment. Researchers adjusted for factors such as education, smoking status, the presence of a particular gene thought to predict dementia, and history of stroke or diabetes.
"We aren't suggesting that people should take statins for purposes other than what they are indicated for, but hopefully this study and others will open the door to statin testing for dementia and other types of cognitive impairment," Haan said.
It's not clear exactly how statins work to decrease the development of dementia. An emerging risk factor for dementia is high insulin, Haan said, and one theory is that statins may work on those insulin pathways in a way that lowers the high insulin levels in the brain that can lead to the classic Alzheimer's pathology.
Statins lowered the risk of dementia in all participants, but the statins had more of an impact on the group at high risk due to metabolic syndrome. The next step, Haan said, is to determine exactly how the statins work on the biochemical pathways involved in dementia.
The research is funded by the National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, and the American Health Assistance Foundation. Co-authors include Caryn Cramer and Sandro Galea of the U-M SPH Department of Epidemiology, Kenneth Langa of the U-M Division of General and Internal Medicine and U-M Institute for Social Research and John Kalbfleisch of U-M SPH Department of Biostatistics.
The University of Michigan School of Public Health has been working to promote health and prevent disease since 1941, and is consistently ranked among the top five public health schools in the nation. Faculty and students in the school's five academic departments and dozens of collaborative centers and initiatives are forging new solutions to the complex health challenges of today, including chronic disease, health care quality and finance, emerging genetic technologies, climate change, socioeconomic inequalities and their impact on health, infectious disease, and the globalization of health. Whether making new discoveries in the lab or researching and educating in the field, SPH faculty, students and alumni are deployed around the globe to promote and protect our health.
Mary HaanSchool of Public Health